Sonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn® (hypochlorous acid) for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars
June 20, 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
Sonoma Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017
June 05, 2017 16:05 ET
|
Sonoma Pharmaceuticals, Inc.
Product revenue for fourth quarter up 60% and for fiscal year 2017 up 48%, compared to last year, driven by growth in U.S. dermatology salesCash position of $17.5 million; management believes the...
Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2017 Financial Results and Conference Call
June 02, 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., June 02, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal year and fourth quarter...
Sonoma Pharmaceuticals Receives Two New United Arab Emirates Regulatory Approvals: Pediacyn® for Atopic Dermatitis and Epicyn® for Scar Management
April 12, 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., April 12, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
Sonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon® Skin Descaler for Relief of Scaling Associated with Various Dermatoses
March 29, 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
Sonoma Pharmaceuticals Receives Final $1.5 Million Payment From Sale of Latin America Business to Invekra S.A.P.I. de C.V.
March 23, 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
Sonoma Pharmaceuticals Announces Results from SebuDerm™ Gel Study in Treatment of Seborrheic Dermatitis
March 16, 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
Evaluation of SebuDerm (hypochlorous acid) Gel on Mild to Moderate Facial and Scalp Seborrheic DermatitisInvestigator Global Assessment (IGA) Scores Showed a 33% Improvement at Day 14 and a 52%...
PetSmart® Launches the MicrocynAH® Family of Pet Healthcare Products for Dogs, Cats, Birds, Reptiles and Small Animals
February 28, 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PHOENIX and PETALUMA, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that PetSmart, Inc., the leading pet specialty retailer...
Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017
February 09, 2017 16:05 ET
|
Sonoma Pharmaceuticals, Inc.
U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology SalesCash Position of $20.5 Million; More Than Fully Funded to Achieve EBITDA Breakeven Income From Discontinued Operations of...
Sonoma Pharmaceuticals Appoints Marc Umscheid as Chief Strategy and Marketing Officer
January 31, 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced the appointment of Marc Umscheid as chief strategy and marketing...